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ABSTRACT
Knapek, Katie J. M.S., Department of Biological Sciences, Microbiology and Immunology
Program, Wright State University, 2008. The Role of Phospholipase D (PLD) and Grb2 in
Chemotaxis.

Phospholipase D (PLD) is an enzyme that hydrolyzes phosphatidylcholine yielding
choline and phosphatidic acid.

PLD is activated by mitogens (lead to cell division) and

motogens (leading to cell migration). PLD is known to contribute to cellular proliferation and
deregulated expression of PLD has been implicated in several human cancers. PLD has been
found to play a role in leukocyte chemotaxis and adhesion as studied through the formation of
chemokine gradients. We have established a model of cell migration comprising three cell lines:
macrophages RAW 264.7 and LR-5 (for innate defense), and fibroblast COS-7 cells (for wound
healing). COS-7 cells respond to EGF, while the other cell lines respond to MIP-1and MCP-1.
Transfection of cells with either PLD1-WT or PLD2-WT constructs leads to increased
cell chemotaxis. PLD2-WT is better (>1.5-fold) at increasing chemotaxis than PLD1 WT.
Phospholipase inactive mutants in the HKD domain have a negative effect on chemotaxis. Two
PLD2 mutants in the PX domain, Y169F and Y179F, known to inhibit the ability of PLD2 to
bind through an SH2 domain, failed to potentiate chemotaxis. Conversely, mutation created
near, but not in, the SH2 recognition domain in PLD2 (PLD2 Y165F) did not impair the positive
effect on chemotaxis observed for the WT. We have demonstrated also here that a proteinprotein interaction between PLD2 and Grb2 is needed to enhance chemotaxis. Thus, PLD,
signaling through Grb2, is a key regulator of the functionality of the three cells studied. This
may pay an important role in facilitating wound healing and innate defense capabilities of our
body.

iii

TABLE OF CONTENTS

Page
I.

LITERATURE REVIEW…………………………………………………......1

II.

HYPOTHESIS AND SPECIFIC AIMS………………………………….…..17

III.

MATERIALS AND METHODS……………………………………………..19

IV.

RESULTS…………………………………………………………………..…29

V.

CONCLUSIONS………………………………………………………..….…63

VI.

DISCUSSION……………………………………………………………..….64

VII.

SIGNIFICANCE………………………………………………….….…….…69

VIII.

REFERENCES………………………………………………….…………….70

iv

LIST OF FIGURES
Figure

Page

1. The breakdown of phosphatidylcholine by phospholipase D………………..…..…2
2. Schematic representation of PLD1 and PLD2…………………………….…...…...4
3. Major similarities and differences between PLD1 and PLD2……………………...5
4. Amino acid sequence of PLD……………………………………………………...12
5. Methodologies used to study chemotaxis…………………………………..….….30
6. Analysis of a Boyden Chamber membrane after chemotaxis………………..……32
7. Chemotaxis of isolated neutrophils.……………...…………………………..…….33
8. COS-7 and RAW 264.7 time experiments………………………..………….…….34
9. COS-7, RAW 264.7, LR-5 dose experiments………………………………..…….36
10. Transfection of GFP into cell lines…………………………………………….....38
11. Transfection efficiency of plasmids………………………………………………39
12. COS-7 cell empty vector and PLD transfection….………………………….…...40
13. Immunofluorescence of PLD2 WT-transfected human macrophages…………...42
14. Schematic representation of lipase dead mutants……………………………..….43
15. Chemotaxis of lipase dead PLD mutants into cells………………………….…...45
16. Western blots of COS-7 cell lysates from transfected cells……………….……...47
17. Schematic representation of PLD2 YF mutants..………………………….……...48
18. Chemotaxis of PLD2 YF mutants..………………………………………….……49
19. Immunofluorescence of COS-7 cells transfected with PLD2 chimeras…………..51
20. Enzymatic activity of PLD plasmids in COS-7 cells……………………………...52
21. Schematic representation of PLD/Grb2 binding………………………………….53
v

22. Chemotaxis of Grb2 mutants…..………………………………………………….55
23. Schematic representation of Grb2 WT and Grb2 R86K constructs………….……56
24. Immunoprecipitation of COS-7 cells using Anti-Grb2, Anti-HA, and Anti-PLD...57
25. Immunofluorescence of COS-7 cells transfected with Grb2 chimeras……………59
26. Chemotaxis of non-silenced Grb2 and shGrb2 silenced transfected LR-5 cells…..60
27. Proposed model for the participation of PLD2 and Grb2 in chemotaxis……….…62

vi

LIST OF TABLES
Table

Page

1. Primers used in construction of Grb2 and Grb2 R86K plasmids………………….27

vii

ACKNOWLEDGEMENTS
I would like to thank my thesis advisor, Dr. Julian Gomez-Cambronero for his guidance
throughout my research project. I would like to thank the members of my committee, Dr. Nancy
Bigley and Dr. Mill Miller, for all of their support and ideas. I would also like to thank Mauricio
Di Fulvio for the preparation of all plasmid constructs and for his scientific guidance. Last, but
not least, I would like to thank Kathleen Frondorf, Karen Henkels, Floria Peng, Kevin Dougherty
and Allissa Blystone for their friendship and guidance over the last two years.

viii

I. LITERATURE REVIEW
History and Catalyic Activity of Phospholipase D
Phospholipase D (PLD), an enzyme that breaks down phosphatidylcholine (PC) at
the ester linkage between phosphate and the choline group, (Figure 1) was discovered in
plants by Hanahan and Chaikoff (1-3). PLD was later found in animal cell lines in
response to extracellular stimuli (3-5). This enzyme has thus far been identified in
bacteria, protozoa, fungi, plants and animals (5).
PLD is an enzyme capable of carrying two types of reactions:
(described above) and transesterification.

hydrolysis

Transesterification reactions use primary-

alcohols (i.e. butanol or ethanol) as phosphatdiyl-group acceptors. Phospholipase D can
be indirectly measured through the transphosphatidylation activity, whereby the resultant
phosphatidylalcohols are produced. In transesterification reactions the primary alcohol
replaces the water molecule and becomes the nucleophilic acceptor. These alcohols are
not normally found in biological membranes, and they are only produced by PLDs (3, 4).
PLD is also involved in the regulation of essential cellular functions largely due to
the production of second messengers such as phosphatidic acid (PA) and ultimately
diacylglycerol (DAG) (3-10). Once produced, PA is involved in many cellular functions,
ranging from cytoskeletal rearrangement, phagocytosis, vesicle trafficking, exocytosis,
and neuronal and cardiac stimulation (3, 6, 9, 11, 12).

PLD (1 & 2) Structure
There are two isoforms of the mammalian PLD gene, PLD1 and PLD2.

PLD1 cDNA

was cloned from HeLa cells and encodes a 1074-amino acid 120 kDa protein, whereas

1

PLD

R1-O
R2-O

O
O-P-O-CH2-CH2-N-(CH3)3
OPC
Hydrolysis

PA + Choline

Figure 1:
Illustration of the catalysis of the phosphodiester bond of phosphatidylcholine (PC) by
Phospholipase D (PLD). Hydrolysis of PC is broken down into phosphatidic acid (PA)
and choline (C) (Adapted from 3).
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PLD2 is a 933-amino acid 106 kDa protein (3, 6). PLD1 is located on the long arm (q) of
chromosome 3(3q26) (13). PLD2 is located on the short arm (p) of chromosome 17
(17p13) (14). PLD1 and 2 share ~50% amino acid homology (6, 11). There are two
splice variants of PLD2 which are, PLD2a and PLD2b. The variants of PLD2 are
indistinguishable when comparing their function.

Splice variants of PLD1 include:

PLD1a1, PLD1a2, PLD1b1 and PLD1b2 (6, 9). PLD1 and 2 contain two invariable
sequences referred to as HKD motifs (HxKx4Dx(6)GSxN), which are responsible for
their enzymatic activity (10, 15) (Figure 2). Both PLD enzyme isoforms have several
conserved regions such as a PIP2 binding site, a pleckstrin homology (PH) domain, and a
phox homology (PX) domain located at their N-termini (3, 10, 15). The PH domain of
PLD2 enables it to bind SH2/SH3-containing tyrosine kinases (15). The PH domain of
PLD1 mediates protein to phospholipid interactions as well as protein to protein
interactions (11). The PX domain, composed of 100-140 amino acids, has been found in
other proteins related to membrane trafficking and cell signaling (16). Similarities and
differences are shown in Figure 3.

Intracellular Localization of PLD
PLD1 localizes in the nuclear envelope, endoplasmic reticulum (ER), Golgi
apparatus, transport/secretory vesicles and the plasma membrane (3, 16). In HeLa cells, a
human cervical cancer line, Hiroyama and Exton found that PLD1 localizes primarily in
the perinuclear site, as well as in the trans-Golgi apparatus, multivesicular endosomes
and late endosomes (17). However, PLD1 was rarely found in early endosomes (17).
The authors used a GFP-tagged PLD1 co-localized with Anti-CD63 staining in the

3

Figure 2:
Schematic representation of PLD1a and PLD2 genes showing the two HKD domains, the
PX domain as well as the PH domain (7). Areas circled in red are areas of interest
pertaining to this thesis. A notable difference between these genes is the “loop” in PLD1
that is not in PLD2.
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Figure 3:
Basic similarities and differences of the chromosomal location, their splice variants, size,
location, and activators of PLD1 and PLD2.
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perinuclear area (17). Cluster of Differentiation-63 is a gene encoded by a protein
specific for the cell-surface and mediates signal transduction which has roles in motility,
growth, cell development and activation. The anti-CD63 antibody was used to determine
the location of multivesicular endosomes as well as late endosomes.
There seem to be conflicting results of PLD1 localization in the Golgi apparatus.
One explanation for this difference was that different cell lines were used. Using HeLa
cells, Hiroyama and Exton used WGA-conjugated Texas-Red and anti-mannosidase II as
markers for the trans-, cis-, and medial-Golgi apparatus. WGA-Texas-Red had 20%
localization with GFP-PLD1, but there was no co-localization with the anti-mannosidase
II. This indicates that PLD1 localizes in the trans-Golgi apparatus, but not in the cis- or
medial-Golgi (17).

ConA-conjugated Texas-Red was used to stain the endoplasmic

reticulum (ER) to illustrate that PLD1 does not localize in the ER (17). Colley et al.
found PLD1 to be localized in the Golgi apparatus of REF-52 cells (rat embryonic
fibroblast); however, they used antibodies specific for the trans-Golgi apparatus only.
Colley and others found that PLD1 may localize in the endoplasmic reticulum of REF-52
cells (18).
Using the same markers to determine PLD1 localization, Hiroyama and Exton
also determined localization of PLD2. Whereas PLD1 was found to be in intracellular
membranes, PLD2 was found primarily in the plasma membrane (3, 17, 18). PLD2 is
predominant around the cell periphery in comparison to PLD1 (17, 18). A notable
difference that PLD2 has over other plasma membrane proteins in REF-52 cells is that
overexpressed PLD2 results in filopodia function. In one study, activated human Ras
was injected into REF-52 cells and did not induce the production of ventral cellular
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projections like those seen in cells with overexpressing PLD2 (18). Ras is a signal
transduction protein that regulates actin skeletal integrity, proliferation, differentiation,
adhesion, apoptosis and migration. Ras also is able to activate Raf/MEK/ERK pathway,
PI3K, or Ral-GEF leading to cellular migration through the production of lamellopidia
and filopodia.

Regulator Molecules of PLD1 & PLD2
PLD1 and PLD2 isoforms are highly regulated. The low basal activity of PLD1
versus the high basal activity of PLD2 share similarties in how they are regulated, but
there are also differences to be noted (3, 7, 15). One of the crucial activators of PLD1 is
phosphatidylinositol-4,5-bisphosphate (PI(4,5)P2) (3, 19-21). The interaction of PLD and
lipids is highly dependent on PIP2 at least in vitro (10). PIP2 is a polybasic molecule.
The conserved region located within the C-terminus of the PLD subdomain is the specific
region apparently responsible for the regulation of a lipid (i.e. polyphosphoinositide) that
PLD can bind (10, 19, 20).
Phosphatidic acid (PA) is a signaling lipid resulting from PLD activity and is a
precursor to diacylglycerol (DAG), an endogenous activator of protein kinase C (PKC).
Protein kinase C is another regulator of PLD1, and its isoforms ( and ) can directly
activate this enzyme (11, 22). The different isoforms of PKC associate with different
areas of the PLD1 protein. PKC isoform requires amino acids 1-323 to activate PLD1
(3). Certain growth factors (EGF, PDGF) have been found to activate PLD through PKC
(10, 11). PLD1 is also activated by GTPases of Rho, Ral, and ADP ribosylation factor
families (ARF) (10, 20).
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Phospholipase D2 is activated by PIP2 and PKC to a minimal extent (9). It has
been suggested that PLD2 is required for the transportation of membrane receptors from
endosomes back to the plasma membrane through the mediation of Arf6 (23). This was
first proposed because PLD2 was found to localize mainly in the plasma membrane.

Functions of PLD
Functions of PLD have been studied in a variety of cell types and in a number of
cellular functions. For instance, PLD has been found in macrophages, which has been
correlated to phagocytosis of PLD containing macrophages (19). To support this theory
conversely, dominant negative forms of PLD1 and PLD2 were found to inhibit
phagocytosis of macrophages (19).
As part of the innate immune system, neutrophils, as well as fibroblasts, can
produce superoxide that directly kills bacteria (7, 24). Activation of phox leads to
generation of superoxide radicals which can then produce H2O2. This H2O2 can then be
converted into HOCl or other toxic products through other systems (i.e. halidemyeloperoxidase system) (25).

PLD is a regulator of NADPH oxidase, which is

sequentially activated by PA and DAG (24).

After adhesion of neutrophils to the

endothelium, the oxidative burst and degranulation are activated by the action of various
cytokines (26). While PLD promotes the ability of cells to initiate defense mechanisms,
the inhibition of PLD results in a diminished ability of cells to adhere (6).
Taking adhesion one step further, the mechanism of chemotaxis can be examined.
Chemotaxis or direction migration is the ability of a cell to move toward a
chemoattractant or chemical stimuli. Chemoattractants aid to direct cell migration toward
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a specific location to function in defense. An in vitro study involving neutrophils was
conducted to allow for transendothelial migration towards an extracellular matrix (26).
Cells that migrated through the membrane and subsequently adhered to this surface were
then found to synthesize PA and DAG (26).
Some cytokines shown to promote the ability of cells to chemotax include: IL-8,
fMLP (formyl-met-leu-phe), and ENA-78 (epithelial neutrophil-activating peptide-78)
which are specific for neutrophils. Extracellular growth factor (EGF) is a cytokine that is
able to stimulate fibroblasts.
There are also chemokines specific for monocytes and macrophages, which
include: macrophage inflammatory protein 1- (MIP-1), monocytic chemotactic
protein-1 (MCP-1) and macrophage-colony stimulating factor (M-CSF). These cytokines
specific for the cell types listed will be discussed in further detail.

History and Role of Grb2
Growth factor receptor bound protein 2 (Grb2) is a 25 kDa protein composed of
two SH3 domains and one SH2 domain (27, 28). The crystal structure of the SH2
domain of the Grb2 c-src is a central antiparallel -sheet that has two -helices on either
side (29). Peptide binding is mediated by the -sheet, intervening loops and one of the helices (29). As seen with the stimulation of Grb2 by EGF, Grb2 binds to the EGF
receptor either directly or indirectly through phosphotyrosine-containing proteins through
its SH2 domain (15, 27). Other proteins with phosphotyrosine (pTyr) residues include
PLD, Shc, FAK (focal adhesion kinase), Syp and IRS-1. What has been noticeable with
these pTyr residues is they are bound to Grb2 in -turn conformations (27).
9

The two SH3 domains of Grb2 are known to associate with proline-rich areas of
other proteins (28). Son of sevenless (Sos), a protein rich in proline, associates with the
SH3 domain of Grb2. Sos promotes GTP loading of Ras and leads to the activation of
Ras effectors (15).

This Grb2/Sos complex has multiple functions, associated with

embryogenesis, cancer, regulation of the cytoskeleton, cell differentiation and DNA
synthesis (28, 30). Grb2 is a cytoplasmic protein and is able to transmit signals into the
cytoplasm (31). When Grb2 is stimulated with EGF, for example, cytoplasmic Grb2
located in the cytoplasm relocates to the plasma membrane (28).
Overexpression of PLD2 and Grb2 has been found in different types of cancer,
possibly leading to its ability to metastasize. For example, increased amounts of Grb2
have been correlated with formation of tumors in the liver of mice as well as in human
breast cancer cells (27). By inhibiting the Grb2 binding domains with a potential binding
blocker it may be possible to reduce the production of metastatic cells.

Interaction of PLD2 and Grb2
PLD was found to be elevated in cells which have been transformed by several
oncogenes which include v-Src, v-Ras, v-Raf, and v-Fps, leading to the belief that there is
a chronic turnover of PLD-dependent phosphatidylcholine (32). More recently, Grb2 has
been identified as a regulator of PLD2. Novel research has revealed that the tyrosines of
PLD2 Y169 and Y179 are needed in order for Grb2 to interact with PLD2 (Figure 4) (15).
These two residues were found to play differing roles in the function of PLD2. Point
mutation of tyrosine-169 diminishes the enzymatic activity of PLD2, whereas mutation of
the tyrosine-179 diminishes the ability of PLD2 to regulate tyrosine phosphorylation (15,
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28). Both tyrosines are located in the PX domain of PLD2, but only the Y179 residue is
conserved in mammalian PLD2 (15). In vivo studies firmly established the involvement
of the latter tyrosines in Sos recruitment, possibly through Grb2. Supporting this idea is
the knowledge that the SH3 domains of Grb2 interact directly with Sos (15). A double
mutant, PLD2 Y169/179F was not able to bind to the SH2 domain of Grb2 or activate the
Ras pathway (28).
Transfection of a stably-induced short hairpin Grb2 (shGrb2) plasmid silenced
endogenous Grb2 in COS-7 cells, suppressing PLD2 activity (28). Di Fulvio and others
studied the role of Grb2 in PLD activity further by determining whether activity could be
salvaged by transfecting silenced Grb2 cells with a plasmid refractory to shGrb2 plasmid
referred to as xGrb2SiL (28). The cells stably transfected with the shGrb2 plasmid were
then studied using a mutant that was deficient in the SH2 domain, xGrb2SiLR86K (28).
The results showed that the refractory plasmid transfected into COS-7 shGrb2 cells was
able to rescue PLD2 activity however, transfection of a Grb2 plasmid lacking the SH2
domain failed to rescue PLD2 activity. The actual mechanism of Grb2 regulating PLD2
is poorly understood, however the current proposal identifies the tyrosine residues at 169
and 179 as the binding sites for the Grb2 SH2 domain (15, 28).
Once the tyrosine residues mentioned interact with the SH2 domain of Grb2, the
SH3 domain of this protein recruits tyrosine kinases and phosphatases, which have been
found to be important to the functionality of PLD2 (33). Following this idea, a mutant
plasmid, GSTGrb2 P49/206L, was constructed which had the two SH3 domains of Grb2
deleted, resulting in decreased PLD2 activity when transiently transfected into
mammalian cells (15).
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Figure 4:
Sequence of PLD2 showing PX, PH, and HKD domains. Red “Y” indicates functional
tyrosines.
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Later, it was found that decreased activity of PLD2 did not affect the ability of
Grb2 to bind PLD (15, 33). PLD2 lipase inactive mutants (K444R, K758R, K444/758R)
were constructed, transfected into cells and protein was immunoprecipitated from cell
lysates using antibodies to Grb2.

Western blot analysis was then performed using

antibodies against the tagged lipase inactive mutants. Western blotting revealed bands
corresponding to Grb2 binding to the PLD2 mutants thus showing that PLD2-Grb2
binding and activity are not directly associated (15).

EGF, MIP, MCP, M-CSF, IL-8, fMLP, and ENA-78 Chemoattractants
Epidermal growth factor (EGF) triggers two main biological functions in
fibroblasts, namely proliferation and differentiation (34, 35). EGF also serves other
functionsm such as cell rounding, ruffling, actin cytoskeletal reorganization, filopodia
extension and the most important for research conducted herein, cell motility (35). EGF
is a polypeptide that has two sets of anti-parallel-sheet conformations with negligible
-helical arrangement (34). Tyrosines that are autophosphorylated at the EGF receptor Cterminus allow for the binding of Src 2 (SH2) and phosphotyrosine binding (PTB)
domains (35). It has previously been reported that receptor kinase activity along with at
least one of the C-terminal tyrosine autophosphorylation sites are both required for cell
movement (36).

In addition to the latter requirements, both phospholipase C-and

protein kinase C (PKC) have been linked to EGF and its ability to enhance cell motility
(37, 38).
Monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory protein1 (MIP-1) and macrophage-colony stimulating factor (M-CSF) are chemoattractants
13

found to increase cell motility among monocytes/macrophages. MCP-1 and MIP-1,
which have a C-C structure, activate monocytes and induce directional migration (39).
Aside from the ability of MCP-1 to stimulate chemotaxis, it is also able to stimulate
monocytes to become cytostatic for some tumor cells lines, increase levels of intracellular
calcium and induce monocytes to release superoxide anions and lysosomal enzymes (39).
MIP-1 proteins act through G-protein-coupled cell surface receptors that are
expressed by monocytes/macrophages (40).

MIP-1 binds to chemokine receptors

leading to a variety of cell functions including: chemotaxis, degranulation, phagocytosis
and mediator synthesis. Signaling events that are initiated by the previously stated Gprotein complex lead to its dissociation into two subunits: G and G. These two
subunits then activate the PI3K pathway and PLC, relatively (40). Upon activation of
PLC, an influx of Ca2+ activates a protein kinase C isoform (41).
M-CSF plays essential roles in the ability of monocytes to survive, proliferate,
differentiate and mature (41). M-CSF acts by binding to cell surface receptors (CSF-1R)
(42). These cell surface receptors are encoded by the c-fms proto-oncogene. Upon the
binding of M-CSF, the CSF-R1 dimerizes, and the tyrosine kinase domain is activated,
resulting in transphosphorylation of the receptor. Grb2 and PI-3 kinase, two proteins
containing SH2 domains, bind to two of the four phosphotyrosyl residues created (43).
IL-8 and ENA-78 are strong chemoattractants for neutrophils, leukocytes that
play critical roles in angiogenesis, tumor development and wound repair (44, 45). IL-8
and ENA-78 are grouped into a CXC subfamily, where the first cysteine is preceded by
the Glu-Leu-Arg (ELR) sequence of amino acids, thus these chemokines are part of a
group referred to as ELR+CXC (46). These CXC chemokines signal through seven
14

transmembrane G-protein coupled receptors. Specifically, IL-8 is able to bind to CXCR1
and CXCR2 sites, while and ENA-78 binds with a stronger affinity to the CXCR2
receptor site (47). The CXCR-1 receptor site for IL-8 has been shown to activate PLD,1
and CXCR-2 has been shown to activate PLD2.

Like the chemokines previously

discussed, these also signal through cystolic Ca2+ changes as well as through activation of
phospholipase D, subsequent chemotaxis, and exocytosis (48).
N-formyl-methionine-leucine-phenylalanine (fMLP) is a bacterial derived
tripeptide that stimulates neutrophils to migrate towards bacteria (49). FMLP is known to
be produced by enteric flora and contributes to inflammatory bowel disease. Receptors
for this peptide have been found in both monocytes and neutrophils (48). All of the
chemoattractants described were used to stimulate migration of COS-7, RAW 264.7, LR5 and dHL-60 cells, as well blood isolated neutrophils in the current study.

The Physiological Importance of Cellular Migration
Normalcy of migration is found in the ability of leukocytes to move toward
foreign invaders of the body in phagocytic and immunogenic responses. Fibroblasts and
endothelial cells migrate to aid wound repair and become collagen around the wounded
area (50, 51). Migration is also important in embryogenesis and angiogenesis (52).
Cellular migration may be involved in not only the normal physiological state of some
cells, but also in the pathological state. With regard to abnormal migration, the most
common example is viewed in metastasis, whereby tumor cells migrate from the initial
tumor site into the circulatory system where they can then eventually locate to another
site in the body (50). Before migration can occur, cells must orient themselves to
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establish a distinct cell front and rear.

The orientation of the cell depends on the

inflammation site and location of the chemical stimuli or chemoattractants being released
(50, 53).
PA, the product of PLD, has been shown to mediate chemotaxis, as increasing
concentrations of PA lead to a more enhanced rate of cell migration (53). Rac, a small Gprotein downstream target of PLD during actin cytoskeleton rearrangement, is also
involved in cellular migration (54). Actin cytoskeletal rearrangement is subsequently
involved in migration, phagocytosis, and axonal growth mitogenesis, morphological
change and superoxide production (54). While it is still unknown whether PLD is a
primary or secondary regulator of migration, it has been shown by Lehman, et al. that
PLD is a mediator for chemotaxis in COS-7 cells, but it does not affect chemokinesis.
Through the inhibition of PLD, membrane ruffling and formation of lamellipodia
structures are blocked.
In the murine lymphoma cell line EL4, Knoepp, et al. found that activated PLD2
promotes phosphorylation of FAK and Akt, leading to cell-substrate adhesion (54, 55).
However, while inactivated PLD2 inhibits adhesion, migration, proliferation and tumor
invasion, it does not alter the basal level of FAK and Akt phosphorylation (55). Thus, it
is not through these molecules that the inhibitory effects of PLD act (55). Although PA
does play a role in cell migration, the specific mechanisms involved are not completely
understood and more precise structure-function studies are needed.
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II. HYPOTHESIS AND SPECIFIC AIMS
Preliminary observations in our lab have implicated PLD (as part of a complex
intracellular signaling network) in leukocyte migration. IL-8 and related chemokines
stimulate PLD activity and promote chemotaxis. There is a body of evidence of a role for
PLD in chemotaxis in the lab after studies with neutrophils. However, the experimental
use of these cells is somewhat limited in that these cells are not amenable to molecular
biology manipulation (e.g. DNA/RNA transfection) (53). This has been addressed in this
thesis by the use of leukocyte cell lines that are both transfectable and mobile.
Hypothesis
We propose that specific amino acids in the PLD molecule are critical for the
triggering of cell chemotaxis that is mediated by an interaction between PLD and
specific signaling proteins.
Specific Aims
In order to test the hypothesis, we designed the following four specific aims and
conducted experiments directed at testing the main hypothesis.
AIM 1: Identify a suitable cell line that is amenable to transfection and can exhibit
chemotaxis. Neutrophil, monocyte/macrophage and fibroblast cell lines were studied
utilizing a multitude of methods to determine the proper cell line to use for optimal
transfection efficiency. Also, different methodologies to study chemotaxis were invoked
to establish a suitable technique.
AIM 2: Characterize a PLD/chemotaxis relationship by transfection of PLD
plasmids. Plasmid DNA constructs containing the exon for wild-type PLD (1 and 2)
were transfected into cells either by electroporation or using lipofectamine/plus reagents
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and the chemotactic response was quantitated. Next, plasmids containing lipase dead
mutants (PLD1 K860R, PLD2 K444R, PLD2 K758R, PLD2 K444/758R), previously
constructed in our lab (15), were transfected to determine whether the enzymatic activity
of PLD is required for chemotaxis. Specific chemokines were used to study chemotaxis
for specific cell lines depending on the cell type (EGF for COS-7; MIP-1 for LR5). In
addition, immunofluorescence microscopy was used to determine possible intracellular
location of PLD.
AIM 3: Identify PLD mutants that enhance or suppress chemotaxis. PLD mutants
(PLD2 Y169F, PLD2 Y179F, PLD2 Y169/179F, PLD2 Y165F) that had been previously
constructed in our lab (15, 28, 58) were studied to examine the effect of a particular
mutation on the ability of cells to chemotax.
AIM 4: Characterize a protein that can associate with PLD and induce chemotaxis.
Cells were tranfected with Grb2 mutants (Grb2, Grb2ResWT, shGrb2 and xGrb2 R86K),
previously constructed in our lab (15, 28, 58) to determine if overexpression of Grb2
increased chemotaxis, if silencing endogenous Grb2 decreased chemotaxis or if Grb2
binding to PLD could increase chemotaxis.
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III. MATERIALS AND METHODS
Materials
Reduced sodium bicarbonate DMEM, RAW 264.7 and COS-7 cells were obtained
from American Type Culture Collection (ATCC) (Rockville, MD). HPBMC human
peripheral blood monocytes and LGM-3 growth medium were obtained from Cambrex
Bio Science Walkersville, Inc. (Walkersville, MD). Raw 264.7/LR-5 cells were obtained
from Dr. Dianne Cox of Albert Einstein College of Medicine Yeshiva University.
Peripheral blood neutrophils and monocytes were isolated from donated human whole
blood. Histopaque-1077 was obtained from Sigma Aldrich (St. Louis, MO). RPMI 1640
1x was obtained from Mediatech (Manassas, VA). Lipofectamine transfection reagent,
plus reagent and Opti-MEM were purchased from Invitrogen Co. (Carlsbad, CA)
Superfect transfection reagent was obtained from Qiagen (Valencia, CA).

MIP-1,

MCP-1, M-CSF, EGF, IL-3, and ENA-78 were from PeproTech Inc. (Rocky Hill, NJ).
Anti-Protein G agarose, Anti-PLD and Anti-Myc tag monoclonal antibodies were
obtained from Millipore (Temecula, CA). c-Myc antibody conjugated (AC) agarose
mouse monoclonal IgG beads, HA-tag AC agarose mouse monoclonal IgG2a beads and
-actin antibody were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). HAtag mouse mAb was from Cell Signaling (Danves, MA). Triton X- 100, phalloidin-FITC
conjugate (conjugate from Amanita phalloide) and sodium citrate solution were
purchased from Sigma (St. Louis, MO). Enhanced chemiluminescence (ECL) western
blotting detection reagents and Percoll/RediGrad were purchased from GE Healthcare
(Piscataway, NJ). Nucleofector electroporation device, transfection solution V, and GFP
plasmid (pmax-GFP, 3486 bp) were from Amaxa Inc., (Gaithersburg, MD).
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Methods
RAW 264.7 RAW 264.7/LR5 Cell Culture, Viability, and Transfection
RAW 264.7 cells are adherent cells. Upon receipt, cells were thawed quickly,
washed 1x with pre-warmed complete growth medium and centrifuged (800 rpm for 7
minutes). Supernatant was removed, cells were resuspended in fresh complete growth
medium (CGM) consisting of reduced sodium bicarbonate DMEM, 20% FCS (fetal calf
serum) and 1% gentamycin and transferred to tissue culture coated flasks and maintained
at 37◦C in 5% CO2. After 2-3 passages, 10% NCS (newborn calf serum) was substituted
for 20% FCS in the CGM. Cells were fed with fresh CGM every three to four days and,
once confluent, were split 1:4 (cell:media) ratio. Trypan blue exclusion test was used to
determine cell viablility. Viability of cells prior to transfection was > 90%. RAW 264.7
cells were serum starved one day prior to transfection. Cells (~ 3 x 106 per transfection)
were lifted from flask surfaces using cell dissociation buffer, then diluted with an equal
volume of media, pelleted at (700 rpm for 5 minutes) and resuspended in 100l of
Amaxa nucleofection solution V containing the plasmid DNA (1-5g) of interest. Cells,
plasmid DNA and solution V were placed in an electroporation cuvette and then
subjected to an appropriate electric current for an appropriate length of time by the
electroporation instrument. Transfected RAW 264.7 cells were plated in 6-well nontissue coated culture plates containing 2ml/well CGM (no antibiotics). Experiments were
conducted 28.5 hours post-transfection.

LR5 cells were transfected using superfect

reagent (Qiagen). One day prior to transfection LR5 cells were split into 6-well nontissue coated culture plates and maintained in CGM (antibiotic and 10% NCS). At the
time of transfection cells were between 80-85% confluent. A mixture of SuperFect
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reagent, plasmid DNA (1-5g) and CGM (no serum) was incubated for 10 minutes at
room temperature and then added drop-wise onto the adherent monolayer of cells to a
final volume of 2ml per well. Cells were incubated with transfection reagent and plasmid
for ~3 hours after which cells were washed 3 times with CGM, and incubated an
additional 28.5 hours in the presence of CGM prior to experimental use.

COS-7 Cell Culture, Viability, and Transfection
COS-7 cells, like LR-5 and RAW 264.7 cells, grow as an adherent monolayer.
Cultures were established from a frozen stock by washing thawed cells 1x with prewarmed DMEM and placed in coated tissue culture flasks in CGM.

Cells were

maintained in 75cm2 tissue culture coated flasks and, once confluent cells were
trypsinized, counted and subcultured in 6-well culture plates 1 day prior to transfection.
Viability was determined by trypan blue exclusion. On the day of transfection, cells were
washed 2x with warm PBS to remove serum and returned to 37◦C and 5% CO2 with 1ml
per well of pre-warmed Opti-MEM (serum free media). Lipid-DNA complexes were
prepared by mixing lipofectamine reagent, plasmid DNA, plus reagent and Opti-MEM
and incubating at room temperature for 10 minutes according to manufacturer’s
instructions (Invitrogen). Transfection mixtures were added drop-wise to the plated
cultures. Cells were incubated in the transfection media at 37◦C and 5% CO2 for 3 hours.
Transfection media was replaced with 2ml CGM (no antibiotics) after washing 1x with
CGM (no antibiotics). Cells were allowed to grow for 48-55 hours prior to harvesting for
experimentation.
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Neutrophil and Monocyte Peripheral Blood Isolation
Similar to English and Anderson, blood was drawn in a syringe containing 10%
sodium citrate and then slowly added to 6% dextran saline (56). Blood was allowed to
settle (30 minutes), top phase removed, sedimented (~ 700 ref for 3 minutes) and pellet
resuspended in saline. A ficoll (Histopaque) gradient was used to separate leukocytes
and red blood cells (RBCs). Following centrifugation (10000 ref for 15 minutes), the
supernatant containing the pellet consisting of RBCs and polymorphonuclear cells
(PMNs) was resuspended in 1ml saline, then diluted in ice-cold sterile water to lyse
remaining RBCs and returned to isotonic conditions with an equal volume of 1.8%
sodium chloride. Following centrifugation (7 ref for 3 minutes), the resulting pellet
consisting primarily of neutrophils was resuspended in HBSS/Hepes buffer. The cell
concentration was adjusted for experimentation and diluted with the proper volume of
RPMI media.

Chemotaxis
Adherent cells were detached using 25% Trypsin/EDTA or a non-enzymatic cell
dissociation buffer for COS-7 or RAW cells, respectively. A hemocytometer was used to
count cells, and trypan blue exclusion was used to determine cell viability. 24-well plates
and Transwell inserts were pre-wetted with DMEM containing 0.5% BSA.

Cell

concentration was adjusted to 5 x 104 cells per 400l of DMEM containing 0.5% BSA
per insert. 600l of DMEM containing 5% BSA was added to the bottom of the well
prior to placing the cells and insert in the well. Either 10 nM macrophage inflammatory
protein (MIP-1) for RAW 264.7 and RAW 264.7/LR5 cells or 100 ng/l EGF for COS-
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7 cells were used as chemoattractants. The murine macrophage cells lines were allowed
to chemotax for 3.5 hours and COS-7 cells chemotaxed for 1 hour at 37◦C, 5% CO2.
Afterward, inserts were removed and cells that had migrated to the bottom were fixed
with 4% paraformaldehyde per each well. Cells that migrated to the bottom were then
allowed to settle and adhere before being counted. Cells were then counted using an
inverted microscope at 20x. The average numbers of 6 counts per well were taken and
data is quantified.

Cell Lysate Preparation
Lysates of cells were taken at 28 and 48 hours after transfection for RAW/LR-5
cells and COS-7 cells respectively. Lysates were prepared using a lysis buffer containing
0.4% Titron X-100 and protease inhibitors, aprotinin and leupeptin (referred to as SLB).
Cells were washed 2x with ice cold PBS, then scraped from wells and pelleted. Cell
pellets were resuspended in 150 l of ice cold SLB and sonicated twice for 10 seconds.
An aliquot was removed from each sonicate to determine protein concentration using
BioRad protein assay and total protein was detected at O.D. 595 nm using an Amersham
BioTrack II plate reader.

Western Blotting
Transfected cell sonicates were subjected to SDS-PAGE using Pierce 4-20%
Precise Protein gels and Trichrom Ranger Prestained Molecular Weight Markers. Gels
were run at 120 Volts for approximately 45 minutes.

Proteins from the gel were

transferred to PVDF membranes at 60mA for 2 hours. The membranes were incubated in
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5% BSA/TBS-T at 4◦C (blocking buffer) overnight. Western blotting was carried out
using the following dilutions of primary antibodies in blocking buffer: 1:1000 anti-Myc
(rabbit or mouse IgG), 1:1000 anti-HA (rabbit or mouse IgG), 1:1500 anti-Grb2 (mouse
IgG), 1:3000 anti--Actin (mouse IgG). Washed blots were then incubated in 1:3000
dilutions of the appropriate secondary antibody-HRP conjugate. After washes with TBST Amersham’s ECL reagent was used to activate the horseradish peroxidase, and x-ray
film was exposed to the immunoblots. Film exposures of the blots were taken and
developed 24-48 hours after the incubation of the membrane in primary antibody. Blots
were then mounted in a cassette and autoradiography film was used to visualize the blots.

Immunofluorescence Microscopy
RAW 264.7/LR5 cells transfected with myc- or HA-tagged plasmids were fixed
onto 22mm2 glass coverslips by adding 1ml of 4% paraformaldehyde to each coverslip
for at least 10 minutes. Paraformaldehyde was aspirated off and cells were permeabilized
with 1 ml 0.5% Triton X-100 in PBS for 10 minutes. Cells fixed on coverslips were then
blocked in IF blocking buffer (10% newborn calf serum and 0.1% Triton X-100 in PBS)
for 4 hours. Coverslips were then incubated overnight at 4◦C in the dark in a 1:1000
dilution of anti-HA-FITC or anti–myc FITC IgA conjugate in PBS. Next, coverslips
were washed 3 times for 5 minutes in 1 ml of PBS. Actin staining was carried out using a
1:200 dilution of Phalloidin TRITC in PBS for 2 hours at room temperature. Following
washing, a final stain using DAPI, diluted in 1:2000 PBS, was used to stain cell nuclei by
incubating coverslips for 5 minutes and then once again washing with PBS. Excess
liquid was aspirated off and cells were washed a final time. Air-dried coverslips were
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then adhered to glass microscope slides (cell side down) using Vectashield mounting
medium for fluorescence (Vector Laboratories, Inc.) and were visualized on a Nikon
Eclipse 50i inverted microscope with MetaVue software.

Construction of Cerulean-C1-Grb2 WT and Cerulean-N1-Grb2 WT
1. Backbone plasmids Cerulean-C1 and Cerulean-N1
Construction of chimeric plasmids began with Homo sapiens growth factor
receptor-bound protein 2 (Grb2) cDNA. P-Cerulean-N1 and -C1 plasmids were provided
as a gift by Dr. Joel Swanson, University of Michigan. Purified DNA on filter paper was
eluted in a sterile eppendorf tube with 30 l ultrapure water. A 1 l aliquot of the
resulting plasmid DNA solution was used to transform DH5 competent cells. Bacteria
were screened for kanamycin (K+) resistance on K+ LB plates. Isolated colonies were
picked and used to inoculate 5 ml luria broth (LB-K+). The Escherichia coli were grown
overnight at 37oC with 350 rpm aeration until the cultures were turbid.

Plasmids

Cerulean-C1 and Cerulean-N1 were purified using Qiagen QIAprep Spin Miniprep kit.

2. PCR amplification of Grb2 WT and mutant Grb2 R86K cDNA
Grb2 and its mutant Grb2 R86K (the 86 amino acid R was mutated to K) were
cloned into pcDNA 3.1 to yield pcDNA-Grb2 WT and pcDNA-Grb2R86K. The Grb2
WT and Grb2 R86 fragments were ampilified using Pfu polymerase (Primers used are in
Table 1). Primers were purified using PCR for thirty-six cycles: 95oC, 2 minutes, 95oC,
45 seconds, 55oC, 1 minute, 72oC, 6 minutes and 72oC, 10 minutes. Final products were
stored at 4oC indefinitely.

The PCR product was gel purified with Qiaquick Gel

Extraction Kit, then ligated to pCR-Blunt II-TOPO with Zero Blunt TOPO PCR cloning
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Forward primer

GAGTCGACATGGAAGCCATC

Tm=55.6

Reverse primer 1

ATCCGCGGTTAGACGTTC

Tm=54.8 for mCFP-C1

Reverse primer 2

CCGCGGGACGTTCCGGTTCAC

Tm=65.4 for mCFP-N1

Table 1:
Primers used in ligation for Grb2 WT and Grb2 R86K.
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kit according to manufacture’s instructions. The ligation reactions were kept on ice and
transformed into DH5 competent cells.

Colonies positive for the plasmids were

screened on LB/K+ agar plates. Isolated colonies were used to inoculate luria broth (LB,
K+) and cultures were grown overnight at 37oC with 350 rpm aeration. Mini preparation
of purified plasmid DNA was performed for Grb2 WT and Grb2 R86K ligated into the
TOPO plasmid. Plasmid verification was performed using PCR and restriction enzyme
digestion (RED).

3. Digestion and ligation
The TOPO-Grb2WT and TOPO-Grb2R86K plasmids were digested with
restriction enzyme Sal I and Sac II, sequentially.

During this time, the backbone

plasmids containing the fluorescent protein coding region, Cerulean C1 and Cerulean N1,
were also digested using these same two restriction enzymes. The digested fragments
(backbone fragments, Grb2 WT and Grb2 R86K) were purified with the gel purification
kit listed above, and the backbone fragments were treated with T4 DNA polymerase to
avoid plasmid self-ligation. The Cerulean and Grb2 fragments were ligated overnight at
4oC with T4 DNA ligase. The ligation product obtained was used to transform DH5
cells which were then spread onto a LB/K+ agar plate. Colonies that grew on K+ plate
were picked randomly and used to inoculate to 5 ml LB/K+ media for plasmid extraction.

4. PCR and Restriction Enyzme Digestion (RED) for positive colony identification
The Grb2 forward and backward primers were used for PCR identification for the
recombinant plasmids. The PCR positive plasmids were extracted using Qiagen QIAspin
Miniprep Kit and subjected to RED. Size and restriction map of each of the plasmids
was verified by RED (~ 5300 bp).

Plasmids identified as recombinant ones were

sequence verified.
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5. Maxiprep for the verified plasmids
E. coli colonies containing verified plasmids were grown in 2L LB media and
maximum preparations of the purified DNA plasmids were made using Mo Bio
UltraClean Plasmid Prep Kit.

Concentrations and purity of plasmid DNA was

determined by spectrophotometry at OD260/280. Purified plasmid DNA was used for
transient transfections.
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IV. RESULTS
AIM 1: Identify a suitable cell line that is amenable to transfection and can exhibit
chemotaxis.
We chose for this thesis three cell types: two macrophage-derived lines (RAW
264.7 and LR-5) and a fibroblast-derived cell line (COS-7).

We wanted first to

understand if the cells were amenable to DNA/RNA transfection and if they were
responsive to chemoattractants.

Available strategies for transfecting cells include

lipofectamine and plus reagent, superfect and electroporation solution V (Amaxa,
Gaithersburg, MD) for COS-7, LR-5 and RAW 264.7 cells respectively. These products
are suitable (at different levels) to use on the adherent cells studied. Prior to transfection,
cells were found to be >90% viability by trypan blue exclusion. Following transfection,
viability remained stable except when using electroporation with RAW 264.7 cells,
which had an average viability of 20% post-transfection. Several different methodologies
for measuring chemotaxis were studied including boyden chamber densitometry and
Transwell quantitation (Figure 5). Only human peripheral white blood cells studied
(neutrophils and monocytes/macrophages) were found to yield positive results in the
Boyden chamber, which were used initially as a positive control for chemotaxis (50)
(Figure 5A). Figure 2 is a representation of the Boyden chamber after cells adhered to
the underside of the membrane and following were Wright-stained to show areas where
neutrophils adhered to the membrane.
Cancer cell lines used were capable of giving positive results only in Transwell
experiments. Transwells for experimentation were loaded with 5x105 cells per well in a
volume of 400l. A representative procedure of transwell chemotaxis is shown in Figure
29

Figure 5:
Methodologies used in performing chemotaxis. (A) An example of a 12 m pore size
filter membrane with cells stained with Wright Stain. (B) Transwell basic procedure that
has 2 compartments separated by a semi-permeable membrane.
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3B using LR-5 as the experimental cell line. It was established that transwells were the
best means to study a multitude of cell lines and their reactions to chemoattractants.
A. Establish the chemotactic response of neutrophils to standard chemoattractants.
The upper compartments of the Boyden chamber were loaded with neutrophils,
while the lower compartments received varying amounts of IL-8 (1.5, 2.5, 12.5 and 25
nM), fMLP (15, 150, and 300 nM), and ENA-78 (10, 30, and 50 nM) (Figure 6) (44, 49).
Through this experiment IL-8 and FMLP showed neutrophils extracted from human
blood were able to stimulate chemotaxis in a dose-dependent manner best. Neutrophils
that were tested showed significant migration in the Boyden chamber in all
concentrations of FMLP as well as IL-8 at 12.5 and 25 nM (Figure 7). All concentrations
of fMLP were significant and they showed hyperbolic responses.

B. Study the chemotactic response of three motile cell lines through dose and time
dependency.
1. RAW 264.7 Cells, a macrophage cell line that responds to MIP and MCP.
RAW 264.7 cells are a murine macrophage cell line obtained from ATCC. Cells
used in these experiments were between passages ten and fifteen. RAW 264.7 cells can
be stimulated by many chemoattractants including: MIP-1, MCP-1, and M-CSF. The
RAW 264.7 cells were found to be stimulated best by MIP-1 at a 10 nM concentration
for three hours rather than a 10nM concentration of MCP-1 (Figure 8A). MCP-1 was
found to stimulate chemotaxis but not to the magnitude of MIP-1. For the studies
conducted herein, MIP-1 was the chemoattracant of choice used to stimulate RAW
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Figure 6:
Analysis of a Boyden chamber membrane after chemotaxis. Peripheral blood neutrophils
were resuspended in RPMI-based chemotaxis bufer at a concentration of 5 x 105 cells/mL
density and placed in the upper chamber of a 5 m pore membrane in the original
Boyden chamber. Bottom wells contained either buffer only or varying amounts of IL-8,
fMLP, or ENA-78.
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Figure 7:
Chemotactic response of human blood neutrophils toward the indicated concentration and
type of chemoattractants. (* indicates p-value < .05 with respect to “control”.)
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Figure 8:
Time-dependency of chemotaxis (A) RAW 264.7 cells were studied in a time-dependent
manner using 10 nM of MIP (blue circles) and 10 nM MCP (red squares). (B) COS-7
cells were studied at an EGF concentration of 100 ng/l at 30 minute increments over a
period of 120 minutes.
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264.7 and LR-5 cells due to its significance (Figure 9B and C). M-CSF could also be
used to stimulate chemotaxis (data not shown).
2. LR-5 cells, also a macrophage cell line which is stably expressing the Lac
repressor and are proven to be more mobile than the parental RAW 264.7 cells.
A dose response experiment was also performed using LR-5 cells, which were
provided by Dr. Diane Cox, Albert Einstein School of Medicine Yeshiva University, NY.
Dr. Cox’s laboratory found LR-5 cells to be more mobile than RAW 264.7 using live-cell
microscopy. LR-5 cells are murine macrophages that stably express the Lac repressor
derived from RAW 264.7. Cells were used for dose and time experiments between
passages ten and fifteen.

Like the RAW 264.7 cells, LR-5 cells, are found to be

stimulated by the same chemoattractants (Figure 9C).
3. COS-7 cells, a fibroblast cell line that is stimulated by EGF.
COS-7 cells are fibroblast cells, which grow in the presence of EGF (33). COS-7
cells were used in cell migration to develop a model for wound healing. Fibroblasts
synthesize collagen and maintain the structural integrity of connective tissue and we have
found that EGF could also act as a chemoattractant.

Dose and time dependent

experiments were used with COS-7 cells between passages ten and twenty. Dose and
time response experiments revealed experimental optimization at 100 ng/l EGF and for
one hour.
We have established a model of cellular migration that is comprised of three cell
lines that exceed our expectations when compared to neutrophils. RAW 264.7 is a
murine macrophage cell line that responds very well to MIP-1 and to a lesser extent,
MCP-1 in a dose and time dependent manner. As reported by the laboratory that first
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Figure 9:
Dose response of chemotaxis. (A) COS-7 (B) RAW 264.7 and (C) LR-5 cells stimulated
with their respective chemoattractants. COS-7 cells were chemotaxed for 1 hour while
RAW 264.7 and LR-5 cells were chemotaxed over a period of 3 hours. ( * are p<0.05
with respect to no chemoattractant (B) or Mock (C).)
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identified them (Dr. Diane Cox, Albert Einstein School of Medicine, New York) LR-5s is
a murine macrophage cell line stably expressing the lac repressor that is: (1) more mobile
and (2) more easily transfectable than the parental counterpart RAW 264.7 cells. Like
the previous macrophage cell line mentioned, LR-5 cells also respond to MIP-1 and
MCP-1 in a similar manner. COS-7 cells on the other hand are fibroblastic in nature and
migrate towards EGF in a dose dependent manner as illustrated (Figure 9C).
AIM 2:

Characterize a PLD/chemotaxis relationship by transfection of PLD

plasmids.
Cells utilized in the following section were transfected with green fluorescent
protein (GFP) to determine transfection efficiency using the strategies indicated in Aim 1
(Figures 10 and 11). RAW 264.7 cells were electroporated using amaxa nucleofector
solution V at 3x106 cells per condition, which resulted in 25% viability and 18% average
transfection efficiency for plasmids (Figure 11). Transfection efficiency and viability
was greater for LR-5 and COS-7 cells than that of RAW 264.7. Viabilities of the latter
cells lines (LR-5 and COS-7) were both >90% following transfection with GFP.
Transfection efficiencies of these cell lines were 40% and 83%, respectively.
COS-7 cells were transfected with phospholipase D (PLD) 1 and 2 wild-type
plasmids in phCMV and pcDNA 3.1 vectors to determine if an overexpression of PLD
was able to increase chemotaxis. To create a control for this experiment, empty vector
plasmids were transfected into COS-7 cells and compared with the mock control and the
PLD plasmids. The empty vector transfections were not significantly different from the
mock (Figure 12). These results conclude that transfection alone does not alter the cell in
any way structurally or metabolically that adversely or directly impacts chemotaxis. We
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Figure 10:
Control experiments with Green Fluorescent Protein (GFP)-expressing cells. (A) and (B)
RAW 264.7 cells, (C) and (D) LR-5 cells, (E) and (F) COS-7 cells (A,C,E) mock
transfected and (B, D, F) GFP transfected using Amaxa Solution V, Superfect and
Lipofectamine and Plus reagent respectively.
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Figure 11:
Transfection efficiency of pmax GFP using manufacturer’s recommended methodologies
and parameters for the respective cell lines.
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Figure 12:
Control experiment ruling out a side effect of the empty vectors. COS-7 cells were
transfected with the PLD1 and PLD2 mutants and their respective empty vectors
(phCMV2 and pcDNA 3.1) to show that chemotaxis is not a mere product of transfection.
(* are p-values of <0.05 with respect to Mock.)
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can then conclude that overexpression of phospholipase D leads to a 2-fold increase in
chemotaxis and since no attempts were made to separate expressing cells from nonexpressing cells, it may be reasonable to conclude that the observed effect in enhanced
chemotaxis could very well be underestimated.
A. Transfect cells with PLD1 and PLD2 (WT) constructs. Analyze cells studied
through immunofluorescence, assess the transfection efficiency of cells and run
controls with empty vectors to show no specificity toward transfection.
COS-7 cells transfected with the PLD1 and PLD2 WT constructs enhance
chemotaxis when stimulated with EGF (at p-values <0.05) and these results foreshadow
the cellular changes induced by PLD during EGF-mediated chemotaxis. PLD is an
enzyme that has been connected to leukocyte function and migration. The cells studied
in this thesis initially have small amounts of endogenous PLD. Through transfection of
the PLD2 WT plasmid, stimulation of MIP-1 or MCP-1 for ten minutes leads to
structural changes, which were visualized using immunofluorescence (Figure 13). After
transfection of PLD2 the cell remains in an elongated morphology, but when stimulated
with a chemoattractant, the cell cytoskeleton changes from an elongated shape to
compact and migratory (57).
COS-7, RAW 264.7 and LR-5 cells were transfected with a multitude of plasmids
that were previously constructed by researchers within our laboratory.

The PLD1

K830R, PLD2 K444R, PLD2 K758R, and PLD2 K444/758R constructs are mutants that
are lipase dead. Figure 14 is a schematic representation of PLD1 and PLD2 lipase dead
constructs. The lipase dead mutant on the PLD1 isoform is located within the second
HKD domain of the gene. The PLD2 isoforms lipase dead mutants (444 and 758) are
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Figure 13:
Visualization of PLD in human macrophages. Human macrophages (from Cambrex
Walkersville, MD) were transfected with the PLD2 WT construct tagged with myc.
Column A is stained with a FITC antibody against myc to show fluorescence. Column B
is Phalloidin TRITC antibody that reveals -actin. Column C are the nuclei of cells
stained with DAPI. Column C is the overlay of A,B,C where the areas of light green are
areas of PLD expression. Row 1 of these cells is a PLD2 WT transfected cell with no
stimulation. Row 2 is a PLD2 WT transfected cell with MIP-1 stimulation for ten
minutes.

Row 3 is a PLD2 WT transfected cell with MCP-1 stimulation for ten

minutes.
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Figure 14:
Phospholipase D isoforms showing locations of the lipase dead mutants on PLD1 and
PLD2 isoforms. HKD domains are numbered according to their order on the gene.
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located in the first and second HKD domains respectively.

The HKD

(HxKx4Dx(6)GSxN) domains of PLD are invariable regions that are responsible for their
enzymatic activity of PLD (10, 15). The difference between these two regions is a loop
section between the first and second HKD motif of PLD1 (Figure 2).
B. Study chemotaxis
Chemotaxis assays were conducted in COS-7, RAW 264.7, and LR-5 cells.
These cells both play roles in the innate immune response. Both cells lines migrate to
injured areas within the body. Fibroblasts aid in wound healing by synthesizing the
production of collagen. These cells are important in maintaining the structural integrity
of connective tissues. Fibroblasts transfected with PLD2 WT construct significantly
enhanced chemotaxis when stimulated with EGF, a four-fold increase when compared to
mock (Figure 15A). All other plasmids were significantly less mobile than the PLD2 WT
construct possibly detailing that the HKD domain of PLD2 may be an important region of
the protein in chemotaxis. Because there was not a significant difference between mock,
PLD1 WT and PLD1 K830R, the HKD domain of PLD1 WT may not be as involved in
chemotaxis as PLD2 may be.
Macrophages are antigen-presenting cells that have the ability to phagocytose
debris and dead cells. Macrophages are monocytes that have migrated to tissues in the
case of injury or foreign invasion (bacteria). In both macrophage cell lines studied,
(RAW 264.7 and LR-5) PLD2 WT was able to increase the rate of chemotaxis as in
COS-7 cells (compare Figures 15B and 15C to Figure 15A). All PLD2 lipase inactive
mutants were significantly reduced compared to the PLD2 WT plasmid in both
macrophage cell lines. Unexpectedly in LR-5 cells, PLD1 WT was significantly different
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Figure 15:
Study of chemotaxis after transfection with PLD constructs. (A) COS-7, (B) RAW 264.7,
and (C) LR-5 cells with PLD1 and PLD2 WT constructs and lipase inactive mutants of
PLD1 and PLD2 (“KR”). Values are the means + the SEM of three experiments and
asterisks indicate significant difference from values obtained with corresponding WT
PLD (*, p < 0.05).
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from the mock and PLD1 K830R suggesting that in this cell line the first HKD domain of
PLD1 may be involved in chemotaxis contrary to COS-7 and RAW 264.7 results.
C. Run controls by immunoblotting to determine equal expression of plasmids.
-actin immunoreactivity was used as a gel loading control to show equal protein
expression of transfected COS-7 cell lysates. PLD1 WT and PLD1 KR constructs were
transfected equally to yield equal expression of PLD1 (Figure 16A). PLD2 WT and KR
constructs also had relatively equal expression of PLD2 (Figure 16B). In LR-5 cells
lipase inactive mutants PLD2 K444R and PLD2 K444/758R were not significantly
different from the mock. In conclusion transfection of PLD2 WT constructs into RAW
264.7, LR-5, and COS-7 cells leads to an increase in chemotaxis. Conversely, after
transfection of PLD1 WT chemotaxis is enhanced only in LR-5 cells. The phospholipase
inactive mutants residing in the HKD domain(s) of the isoforms have no enhancement
effect on chemotaxis (compare Figure 20 and Figure 15).
AIM 3: Identify new PLD mutants that enhance or suppress chemotaxis.
A. Transfect cells with YF point mutants in the Phox domain of PLD and study
chemotaxis.
Cell lines studied were transfected with mutants with a point mutation at a
tyrosine.

The sites of the point mutations are represented in Figure 17.

After

phosphorylation, tyrosines at the 169 and 179 sites are able to bind to the SH2 motif of
other proteins. Transfection of all YF mutants was found to be significantly different
than PLD2 WT in all cell lines (Figure 18). The ability of tyrosines in the PX domain of
PLD2 to be phosphorylated by various kinases has a large effect on the ability of cells to
chemotax. In LR-5 cells, the Y165F mutant significantly increases chemotaxis when

46

Figure 16:
Western blots of transfected plasmids in COS-7 cells to show similar levels of
expression. (A) PLD1 WT and PLD1 KR expression. (B) PLD2 WT, PLD2 KR, and
PLD2 YF expression. (C) Grb2 WT and Grb2Res WT expression after transfection. PLD1
WT and KR are tagged with HA, while PLD2 WT and its mutants are tagged with myc.
Grb2 constructs are not tagged and thus an antibody specific for Grb2 was used.
Western-blots probed were transfected with -actin to show equal loading. O/Ex =
overexpressed. Endo = endogenous.
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Figure 17:
Schematic representation of YF mutantions of the PLD2 gene. After phosphorylation,
Y169 and Y179 sites are able to bind an SH2 region of other proteins.
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Figure 18:
Chemotaxis after cell transfection with PLD2 WT and YF mutants. (A) COS-7 cells (B)
RAW 264.7 and (C) LR-5 cells. Values are the means + the SEM of three experiments
and asterisks indicate significant difference from values obtained with corresponding WT
PLD (*, p < 0.05).
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compared to PLD2 WT (Figure 18C). All mutants transfected into the RAW 264.7 and
COS-7 cells had a chemotaxis result significantly less than PLD2 WT construct, but
significantly greater than the mock.
B. Run controls of the YF mutants by immunoblotting and immunofluorescence.
Immunoblotts of the YF mutants were performed to ascertain that chemotaxis was
due to overexpression of the PLD2 constructs and not because of an unequal expression
of protein (Figure 16B). Plasmids were compared with a mock transfection of COS-7
cells, which have little to no endogenous PLD. COS-7 cells were also transfected with
PLD2 WT and PLD2 Y165F that express a yellow fluorescent protein (YFP) upstream of
the PLD protein of interest (Figure 19). PLD2 is identified by the yellow portions around
the nucleus.
C. Investigate whether enzymatic activity of PLD is necessary for chemotaxis
Enzymatic activity of PLD was determined using the procedure in the Materials
and Method section of this thesis. PLD1 K830R has little to no enzymatic activity when
compared to PLD1 WT (Figure 20), but its ability to chemotax is not significantly
different than either of the PLD1 constructs in COS-7 and RAW 264.7 cells (Figure 15A
and B). The reduced cell migration of the lipase inactive mutants of PLD2 may correlate
to the significant decrease in enzymatic activity between these mutants and the PLD2
WT. Mutation on 165 does not affect the activity of the enzyme (and mutation does not
effect chemotaxis). Mutations of the 169 and 179 amino acids are part of the SH2
binding motifs in the PX domain and it can be theorized that chemotaxis is mediated by
the ability of PLD to bind through those sites. However, only mutation on 169 affects the
enzymatic activity. Therefore, the effect of 169 on chemotaxis can be mediated through
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Figure 19:
Fluorescence of cells transfected with PLD chimeras. COS-7 cells transfected with (A)
YFP-PLD2 WT and (B) YFP-PLD2 Y165F chimeras. Yellow fluorescence indicates
PLD2 localization (white arrow heads). Blue is DAPI staining of the nuclei.
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Figure 20:
PLD enzymatic activity of cells after transfection with PLD constructs. (A) PLD1 WT
and KR and (B) PLD2 WT, KR, and YF constructs in COS-7 cells. In (A) * is p-value
<0.05 with respect to Mock values. In (B) * are p-values <0.05 with respect to WT
values.
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Figure 21:
Schematic representation of PLD binding to the SH2 region of the Grb2 protein.

53

PA while 179 mediates only protein-protein interactions.
AIM 4: Characterize a new protein that can associate with PLD and induce
chemotaxis.
It was proposed that the 169 and 179 tyrosines of PLD2 served as the binding
domain of an SH2 motif (Figure 20), such as that of the growth receptor binding domain
2 protein (Grb2) (Figure 21) (15, 28). The SH3 domain of Grb2 is able to recruit tyrosine
kinases and phosphatases which have been found to be important to the functionality of
PLD2 (33). The Grb2 protein has been found in many types of cancer possibly leading to
an increased ability of a cell to metastasize.
A. Transfect cells with Grb2 constructs and study chemotaxis.
Western Blotting of Grb2 constructs were transfected equally to yield equal
expression of exogenous Grb2, which is the upper band of Figure 16C while the lower
band is endogenous Grb2. The exogenous Grb2 has a molecule weight due to the
Xpress-tag on the Grb2 plasmids. -actin immunoreactivity was used a loading control.
In all 3 cell lines (Figure 22) we observed a consistently significant increase of
chemotaxis after Grb2 transfection. Conversely, when LR-5 cells were transfected with a
deficient SH2 domain, as with Grb2 R86K (Figure 22C), chemotaxis was completely
negated similar to mock (Figure 22).

The mock and Grb2 R86K results were not

significantly different this indicates that at least a component of chemotaxis is dependent
on Grb2.
B. Determine a possible association of PLD and Grb2 through immunoprecipitation
and immunofluorescence.
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Figure 22:
Chemotaxis of cells after transfection with Grb2 constructs. COS-7, RAW 264.7, and
LR-5 cells were used. Values are the means + the SEM of three experiments and
asterisks indicate significant difference from values obtained with corresponding WT
PLD (*, p-value are < 0.05 with respect to their Mock controls).
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Figure 23:
Schematic representation of Grb2 WT and Grb2 R86K constructs (15).
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Figure 24:
COS-7 cells immunoprecipitated (IP) with (A) anti-Grb2 and western blotted for antiGrb2; (B) IP with anti-PLD and western blotted for anti-Grb2; and (C) IP with anti-Grb2
and western blotted for anti-HA. O/E = overexpressed.
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Cell lysates were prepared after transfection of PLD2 WT, PLD1 WT, PLD1
K830R constructs, as well as the Grb2-WT, Grb2Res (a variation of Grb2, also WT) and
shGrb2 (silencing) constructs.

Immunoprecipitation (IP) was performed to detect a

relationship between PLD(1 or 2) and Grb2. IP with a Grb2 antibody pulled down
endogenous and overexpressed Grb2 in cells untransfected or transfected with
recombinant Grb2 and then immunoprobed with Grb2 antibody (Figure 24A).
Endogenous Grb2 was 100 % in the mock, whereas shGrb2 was approximately 70 %
silenced. Endogenous Grb2 was also detected in lysates of cells transfected with PLD1
or PLD2 WT constructs and subsequently pulled down using the Grb2 antibody and then
immunoprobed for Grb2 on a western blot (Figure 24A).
Cells transfected with Grb2 recombinants were immunoprecipitated with antiPLD, which binds endogenous PLD, and were then immunoprobed with anti-Grb2
(Figure 24B). This indicates that endogenous PLD is able to bind, with greater affinity,
to overexpressed Grb2 rather than endogenous Grb2, since there is evidence of Grb2
immunoreactivity in the Grb2 WT and Grb2Res WT lanes only. IP of PLD2 did not pull
down endogenous Grb2, as shown in the mock or shGrb2 transfected samples. Next,
PLD2 WT, PLD1 WT and PLD1 K830R constructs were transfected into cells, which
were then immunoprecipitated with a Grb2 antibody and immunobloted with anti-HA
(specific for overexpressed PLD2 or PLD1 proteins). Immunoreactivities here show
binding between endogenous Grb2 and overexpressed PLD (Figure 24C). COS-7 cells
were transfected with CFP-Grb2 WT and CFP-Grb2 R86K plasmids to show cellular
localization of the Grb2 protein (Figure 25), which appears to localize in the cytoplasm
(27).
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Figure 25:
Immunofluorescence of transfected of COS-7 cells with (A) CFP-Grb2 WT and (B) CFPGrb2 R86K. Lighter blue area, Grb2, localizes in the cytoplasm of the cell (white
arrowheads). Darker blue is DAPI staining of the nuclei (yellow arrowhead).
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Figure 26:
Co-transfection (A) and Silencing (B) of cells, and chemotaxis in LR-5 cells. (* =
Significance compared to Mock p<0.05)
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C. Silence endogenous Grb2 using shGrb2 plasmid.
Grb2 is an SH2-bearing protein and we have observed that transfection of cells
with Grb2 constructs leads to a significant increase in chemotaxis (Figures 22). In
preliminary experiments, we wanted to ascertain if co-transfection of Grb2 and PLD2
would result in a non-additive or an additive or in a synergistic effect on chemotaxis.
Figure 26A indicated that PLD2 and Grb2 result in a modest additive effect. Also
preliminary experiments were performed to determine if, by removing, all of the
endogenous Grb2 using shGrb2 whether chemotaxis would still occur. LR-5 cells were
transfected with the shGrb2 plasmid two days prior to transfection with PLD2 WT, Grb2
WT, Grb2 R86K plasmids (Figure 26B).

In Grb2 silenced cells, all samples were

significantly less migratory than the PLD2 WT plasmid. The additive effect of PLD2 and
Grb2 co-transfection observed in Figure 26A is negated in silenced cells (Figure 26B).
Through the experiments conducted here, we assume an association between
PLD2 and Grb2.

Grb2, a protein containing SH2 domains, when transfected into cells

has significantly greater chemotaxis than the mock, which is only significantly less than
that of PLD2 WT, unless they are co-transfected. By silencing Grb2, the above increase
seen above with co-transfection is abrogated.

During cell migration Grb2/PLD

interaction is mediated by chemoattractants.
D. Proposed Model for participation of PLD in chemotaxis
Figure 27 presents our proposed model based on results in this thesis, along with
those of other authors that could explain the participation of PLD and Grb2 in cell
chemotaxis.
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Figure 27:
Proposed model for the participation of PLD2 and Grb2 in chemotaxis. Three major
pathways are considered here. First [1-5], PLD uses its activity to produce PA that binds
to target proteins mTOR [2], S6K [3] or Sos [4] (60-62). S6K has been proposed to
stimulate actin polymerization [5] (63). Results in this thesis seem to indicate that Y169 is
involved in enzyme activity (PA production) leading to chemotaxis. Second [6-9], PLD,
independently of its activity, can bind to either Sos or Grb2 [6, 7] (8, 15). Results in this
thesis indicate that Y179 is involved in a PLD2-Grb2 protein-protein interaction
irrespective of enzymatic activity. Grb2 can then possibly activate WASP [8] that also
initiates actin polymerization [9]. Third, PLD can directly interact with actin [10] (64,
65).
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V. CONCLUSIONS
1. We have established a model of cell migration comprising three cell lines, which
compare favorable to neutrophils in regards to their chemotactic response: (a) RAW
264.7 cells, a macrophage cell line that responds to chemoattractants (MCP-1 and MIP1) in a dose and time dependent manner; (b) LR-5 cells, also a macrophage cell line
that is more mobile than the parental RAW 264.7 cells; and (c) COS-7 cells, a fibroblast
cell line that migrates toward EGF.
2. Transfection of cells (RAW 264.7), (LR-5), or (COS-7) with either PLD1 or PLD2
expression constructs leads to an increase in cell chemotaxis. PLD2 is better ( >1.5-fold)
at inducing chemotaxis than PLD1.
3. Phospholipase inactive mutants in the HKD domain, particularly PLD2 KR constructs,
are 2-fold less chemotactic than PLD2 WT, but not significantly different to mock
transfected cells.
4. PLD2 has two functional tyrosines, (Y169 and Y179) that, when mutated, lead to
diminished chemotaxis when compared to PLD2 WT. Since these are mutations of the
SH2 binding motifs in the PLD2 PX domain, we conclude that chemotaxis is mediated by
the PLD’s ability to bind other proteins through these sites. Further, the activity of the
enzyme (production of PA) seems to involve only Y169.
5. We have discovered that Grb2’s SH2 domain interacts with PLD2. Transfection of
cells with Grb2 leads to an augmentation of chemotaxis. The overall conclusion is that
triggering of cell migration by chemoattractants is mediated by PLD, which requires an
association with Grb2.
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VI. DISCUSSION
The results presented in this thesis fall within the overall study of signal
transduction molecules: PLD1, PLD2, and Grb2 and their interaction within a cell.
Three different cell lines (COS-7, RAW 264.7, and LR-5) were examined to determine if
an association of PLD and Grb2 exists during chemotaxis and if it is constant between
different cell lines. We wanted to use cells that were easily amenable to transfection and
could chemotax. The cell lines used are known to play key roles in wound healing during
innate immunity. We used macrophages and fibroblasts to accomplish Aim 1 of this
thesis. Fibroblasts are cells that synthesize collagen in the event of injury to the body and
also maintain connective tissue in animals.

As for macrophages, they are able to

phagocytose debris and bacteria. Macrophages are cells that present antigens to other
cells in order to form antibodies against them.
Within Aim 1, we used RAW 264.7 cells, which are able to be transfected
through electroporation, but result in a significant amount of cell death. This issue has
been resolved at the laboratory of Dr. D. Cox (Albert Einstein College of Medicine) by
creating LR-5 cells, from RAW 264.7 cells, that stably express the lac repressor allowing
them to be transfected using superfect. This new cell line has greatly reduced cell death
using electroporation or lipid-based transfection strategies. All cell lines studied were
able to chemotax within a Transwell, especially when tranfected with the PLD2 WT
plasmid.
Chemoattractants are able to increase the ability of PLD2 to increase the
chemotactic response within the cell lines studied. COS-7 cells are able to be stimulated
by EGF, whereas RAW 264.7 and LR-5 cells are stimulated by MIP-1and MCP-1 in
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chemotactic assays. COS-7 cells achieve maximum chemotaxis when stimulated by EGF
for one hour. Macrophages require three hours for cells to thoroughly migrate through
the membrane of a Transwell to reach the chemoattractant in the bottom of the well.
Transfection of the PLD2 WT plasmid causes a 4-fold increase over the mock
transfected in chemotaxis in the cell lines studied.

The PLD2 KR constructs have

significant decreases in chemotaxis compared to the PLD2 WT plasmid indicating that
PLD activity affects chemotaxis. The method to how these cell lines are transfected are
all different and may leave each cell line in a different state before the chemotaxis
procedure is carried out. We observed that immunofluorescence of RAW 264.7 cells
stimulated with MIP-1 or MCP-1 left macrophages in a compact migratory shape.
Experimentation

of

COS-7

and

LR-5

cells

using

immunofluorescence

and

chemoattractant stimulation would need to be conducted in order to test this idea.
Several PLD2 point mutants have been developed in our laboratory (15, 28) and
their ability to enhance or suppress chemotaxis was studied. We have found that Y169 and
Y179 residues are essential for the association of PLD2 with Grb2 and that this interaction
is independent of PLD2 activity (15, 28). Mutation of Y169 (to Y169F) diminishes
enzymatic activity and mutation of Y179 (to Y179F) diminishes the ability to regulate
tyrosine phosphorylation (28). It has also been noted that Y169 and Y179 residues may
recruit the Grb2/Sos complex which leads to the activation of Ras effectors and
consequently phosphorylation of MEK through Raf (15, 58).

The double mutant,

Y169/179F, was found to be catalytically inactive and was not able to interact with the
Grb2/Sos complex or activate Ras (28). Mutation of Y169 may disable its ability to
activate the Ras/MAPK pathway since its tyrosine can no longer be phosphorylated.
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More so, it has been reported that Y179 regulates total tyrosine phosphorylation of PLD2
and that it uses the Ras/MAPK pathway to negatively monitor cellular proliferation (15).
However, Di Fulvio, et al. have demonstrated that the Y179F plasmid construct leads to
an increase in DNA synthesis (58). Overexpression of Y179F increased Ras activation,
but did not increase cellular proliferation; the mechanism for this is unclear (15). We
have found that both Y169F and Y179F mutants are unable to confer an increase in
chemotaxis.

Since Ras is also able to activate migration, the PLD2 Y179/Grb2/Sos

complex may keep chemotaxis on hold in a similar fashion to how it keeps cellular
proliferation in check, if this is indeed the mechanism that is followed (15). Neither of
these mechanisms are fully understood.
By comparing the transient transfection of Grb2 constructs, specifically Grb2
R86K, we can assume that Grb2 plays a role in chemotaxis. Overexpressed Grb2 R86K,
which cannot bind to PLD through its SH2 domain, is not significantly different from the
mock, but it is significantly different compared to the PLD2 WT or Grb2 WT plasmids.
It has already been shown that PLD2 binds to Grb2 through its SH2 domain (15, 28, 58).
Cells coexpressing PLD2 WT and Grb2Res in stably silenced COS-7 cells were found to
redistribute in the perinuclear Golgi region indicating that PLD2 requires Grb2 to localize
to the Golgi after EGF stimulation (28). There may be a signal in the Golgi that leads to
cellular migration, which is why we see this relocalization after stimulation by EGF.
The effect of a chemoattractant to alter not only localization, but also cell shape is
seen earlier with immunofluorescence of macrophages after MIP-1 or MCP-1 of PLD2
WT transient transfections. Figure 11 shows that macrophages transfected with PLD2
WT maintain their elongated shape, but after chemoattractant stimulation the
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cytoskeletons change to a compact migratory shape. Results of the same nature are seen
in macrophage morphology after transfection of Rac 1/2-/- (57). Membrane ruffling in
lamellipodia is induced through actin polymerization by Rac (57).

The Grb2/Sos

complex leads to activation of Ras, but it may also lead to activation of another GTPase,
Rac, through which macrophage chemotaxis functions (59).
The results presented in this thesis show that PLD is able to affect other signaling
pathways that regulate chemotaxis independently of PLD activity. The PLD2 Y165F
mutant is not part of the SH2 binding motif of Grb2 and thus does not affect binding. We
saw that transfection of PLD2 Y165F leads to a migration that is relatively equal between
the three cell lines. Transfection of the PLD2 WT construct does not cause equal
migration between the cell lines. PLD2 WT enhances chemotaxis the most in RAW
264.7 cells. In RAW 264.7 cells transfection of PLD2 WT causes more migration when
compared to COS-7 and LR-5 cells. We determined that transfection of macrophages
with PLD2 WT plasmid and stimulation with a chemoattractant changes their
morphology, but we would need to do immunofluorescence with the other two cell lines
to determine if a morphological change also occurs.
In relation to COS-7 cells, we know that fibroblasts, by nature, are a slower
migratory cell which may explain of PLD2 WT has less of an effect on their migration
(35). Two tyrosines on PLD bind to Grb2 through its SH2 motif. It is through this
association that PLD has an enhanced chemotactic response. When we alter the enzymes
ability to bind to Grb2 the chemotactic response created with the PLD2 WT construct is
diminished. As seen throughout this thesis, a specific chemokine that is used against a
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specific cell line is not enough to cause a cell to migrate; it requires a signal from an
overexpressed protein to increase the rate of chemotaxis.
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VII. SIGNIFICANCE OF STUDY
The first cell line utilized in this study was COS-7. COS-7 cells are fibroblast
cells, which respond to the growth factor EGF (33). COS-7 cells were used in the
chemotaxis experimental setting of this thesis in order to develop a model for wound
healing.

Fibroblasts synthesize collagen and maintain the structural integrity of

connective tissue and we have found that EGF could also act as a chemoattractant. The
second (RAW 264.7) and third cell (LR-5) lines utilized in this study are both
macrophage-derived. Macrophages are antigen-presenting cells that have the ability to
phagocytose debris and dead cells. Macrophages are monocytes that have migrated to
tissues in the case of injury or foreign invasion and play central roles in the innate
immune response. We have demonstrated that the three cell lines (COS-7, RAW 264.7
and LR-5) are capable of chemotaxing when placed in the presence of an appropriate
stimuli.
Phospholipase D is an enzyme that has been found to play many roles within
mammalian cells and is able to directly or indirectly alter several cell signals. In this
study, we have found that overexpression of PLD, particularly that of the isoform PLD2,
enhanced a cell’s ability to chemotax. We have demonstrated also here that a proteinprotein interaction between PLD2 and Grb2 enhance chemotaxis. Thus, PLD, signaling
through Grb2, is a key regulator of the functionality of the three cells studied. This may
play an important role in facilitating wound healing and innate defense capabilities of our
body.
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